

4 April 2024

Therapeutic Goods Administration warns against replica semaglutide (Ozempic) products

Diabetes Victoria supports the Therapeutic Goods Administration's decision to stop the compounding of semaglutide-like products.

While addressing the shortage of diabetes medicines in Australia is critical, compounding by people who hold no formal qualifications poses a serious risk to human health.

Semaglutide (the active ingredient in Ozempic) is a prescription-only medicine in Australia.

Compounded products are 'unapproved' therapeutic goods that have not been evaluated by the TGA for safety, quality, or efficacy.

The TGA is advising consumers to use extreme caution when purchasing diabetes medicines online.

Products of unknown origin purchased over the internet may contain undisclosed and potentially harmful ingredients.

We encourage the TGA to redouble efforts to increase and improve the supply of diabetes medicines.

If you have compounded semaglutide of unknown origin, or purchased a similar product without a prescription, we recommend you take any remaining vials to your local pharmacy for safe disposal.

Media enquiries:

Britt Denton | bdenton@diabetesvic.org.au | 0488 133 316

